XKRX
000020
Market cap91mUSD
Jul 10, Last price
5,160.00KRW
1D
3.82%
1Q
-12.24%
Jan 2017
-36.45%
Name
Dongwha Pharm Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dongwha Pharm Co., Ltd. is a South Korean entity primarily engaged in the production and distribution of pharmaceutical goods. The company's diverse offerings include prescription-only medications addressing a wide spectrum of health concerns such as digestive and infectious diseases, cardiovascular and metabolic disorders, inflammatory and respiratory conditions, musculoskeletal and neurological ailments, as well as dermatological and urological issues. Furthermore, they market an extensive selection of over-the-counter (OTC) remedies, covering categories like digestive aids, cold and flu treatments, anti-inflammatory and respiratory solutions, skin care, oral hygiene, liver support, nutritional supplements, tonics, topical pain relief, antihistamines, and remedies for sore throats, among other products. Beyond pharmaceuticals, Dongwha Pharm also ventures into quasi-drugs, health supplements, food and beverage items, and cosmetics. Established in 1897, the firm maintains its headquarters in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||